{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Unclassified+Tumor%2C+Malignant&page=3", "query": { "condition": "Unclassified Tumor, Malignant", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 7383, "total_pages": 739, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Unclassified+Tumor%2C+Malignant&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Unclassified+Tumor%2C+Malignant&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T18:12:56.773Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01476137", "title": "A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "GSK1120212", "type": "DRUG" }, { "name": "GSK2110183", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 335, "start_date": "2011-10-26", "completion_date": "2013-03-12", "has_results": false, "last_update_posted_date": "2017-11-13", "last_synced_at": "2026-10-09T18:12:56.773Z", "location_count": 2, "location_summary": "Dallas, Texas • San Antonio, Texas", "locations": [ { "city": "Dallas", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01476137" }, { "nct_id": "NCT04390737", "title": "Evaluate the Safety and Clinical Activity of HH2853", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "FL Lymphoma", "Epithelioid Sarcoma", "Peripheral T Cell Lymphoma", "Advanced Solid Tumor" ], "interventions": [ { "name": "HH2853 Tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Haihe Biopharma Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 254, "start_date": "2020-09-08", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-01-30", "last_synced_at": "2026-10-09T18:12:56.773Z", "location_count": 4, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 1 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04390737" }, { "nct_id": "NCT07637734", "title": "Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Common Warts", "Common Warts (Verruca Vulgaris)", "Human Papilloma Virus (HPV)", "Warts" ], "interventions": [ { "name": "VP-102 (US) / TO-208 (Japan)", "type": "COMBINATION_PRODUCT" }, { "name": "Vehicle (US) / Vehicle (Japan)", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Verrica Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 300, "start_date": "2026-06-15", "completion_date": "2027-07", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-10-09T18:12:56.773Z", "location_count": 12, "location_summary": "San Diego, California • Jacksonville, Florida • Sweetwater, Florida + 9 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Sweetwater", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Skokie", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07637734" }, { "nct_id": "NCT06061809", "title": "N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "PD-L1 t-haNK", "type": "DRUG" }, { "name": "N-803", "type": "DRUG" }, { "name": "Tumor Treating Fields (TTFields, 200 kHz)", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2024-08-07", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-10-09T18:12:56.773Z", "location_count": 4, "location_summary": "El Segundo, California • Fullerton, California • Newport Beach, California + 1 more", "locations": [ { "city": "El Segundo", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06061809" }, { "nct_id": "NCT00900406", "title": "Collecting and Storing Tissue and DNA Samples From Patients Undergoing a Donor Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer", "Chronic Myeloproliferative Disorders", "Gestational Trophoblastic Tumor", "Graft Versus Host Disease", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Neuroblastoma", "Ovarian Cancer", "Testicular Germ Cell Tumor" ], "interventions": [ { "name": "gene expression analysis", "type": "GENETIC" }, { "name": "microarray analysis", "type": "GENETIC" }, { "name": "polymorphism analysis", "type": "GENETIC" }, { "name": "proteomic profiling", "type": "GENETIC" }, { "name": "flow cytometry", "type": "OTHER" }, { "name": "immunologic technique", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "GENETIC", "OTHER", "PROCEDURE" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 190, "start_date": "2007-01", "completion_date": "2010-03", "has_results": false, "last_update_posted_date": "2012-11-06", "last_synced_at": "2026-10-09T18:12:56.773Z", "location_count": 3, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00900406" }, { "nct_id": "NCT01446198", "title": "Clinical Evaluation of the APTIMA® HPV Assay Using the PANTHER™ System", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Human Papilloma Virus Infection" ], "interventions": [], "intervention_types": [], "sponsor": "Gen-Probe, Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 11816, "start_date": "2012-03", "completion_date": "2012-05", "has_results": false, "last_update_posted_date": "2012-07-03", "last_synced_at": "2026-10-09T18:12:56.773Z", "location_count": 3, "location_summary": "San Diego, California • Minneapolis, Minnesota • Burlington, North Carolina", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Burlington", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01446198" }, { "nct_id": "NCT00003404", "title": "Radiation Therapy After Surgery in Treating Women With Phyllodes Tumor of the Breast", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Adjuvant Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "FEMALE", "summary": "18 Years to 120 Years · Female only" }, "enrollment_count": 46, "start_date": "1998-01", "completion_date": "2008-11-17", "has_results": true, "last_update_posted_date": "2019-01-22", "last_synced_at": "2026-10-09T18:12:56.773Z", "location_count": 1, "location_summary": "Lebanon, New Hampshire", "locations": [ { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003404" }, { "nct_id": "NCT06258304", "title": "A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced or Metastatic Solid Tumor Malignancies" ], "interventions": [ { "name": "GIGA-564", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GigaGen, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2024-05-08", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2025-04-10", "last_synced_at": "2026-10-09T18:12:56.773Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06258304" }, { "nct_id": "NCT05627960", "title": "First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Triple Negative Breast Cancer", "Hormone-Resistant Breast Cancer", "Non Small Cell Lung Cancer", "Mesothelioma" ], "interventions": [ { "name": "AG-01 Compound", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "A&G Pharmaceutical Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 77, "start_date": "2022-02-14", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2022-11-28", "last_synced_at": "2026-10-09T18:12:56.773Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05627960" }, { "nct_id": "NCT01254578", "title": "Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11", "Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11", "Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1", "Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A", "Adult Acute Promyelocytic Leukemia With PML-RARA", "Adult Grade III Lymphomatoid Granulomatosis", "Adult Nasal Type Extranodal NK/T-Cell Lymphoma", "Alkylating Agent-Related Acute Myeloid Leukemia", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-Cell Lymphoma", "Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue", "Hepatosplenic T-Cell Lymphoma", "Intraocular Lymphoma", "Lymphomatous Involvement of Non-Cutaneous Extranodal Site", "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma", "Nodal Marginal Zone Lymphoma", "Post-Transplant Lymphoproliferative Disorder", "Primary Cutaneous B-Cell Non-Hodgkin Lymphoma", "Prolymphocytic Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Immunoblastic Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-Cell Leukemia/Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides and Sezary Syndrome", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Richter Syndrome", "Small Intestinal Lymphoma", "Splenic Marginal Zone Lymphoma", "T-Cell Large Granular Lymphocyte Leukemia", "Testicular Lymphoma", "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2010-11-24", "completion_date": "2012-11-09", "has_results": false, "last_update_posted_date": "2017-09-25", "last_synced_at": "2026-10-09T18:12:56.773Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01254578" } ] }